{"id":16038,"date":"2022-03-18T22:37:05","date_gmt":"2022-03-18T17:07:05","guid":{"rendered":"http:\/\/www.sachdevajk.in\/2022\/03\/18\/relationship-of-nifty-50-and-natco-pharma-limited\/"},"modified":"2022-03-20T10:49:35","modified_gmt":"2022-03-20T05:19:35","slug":"relationship-of-nifty-50-and-natco-pharma-limited","status":"publish","type":"post","link":"http:\/\/www.sachdevajk.in\/?p=16038","title":{"rendered":"Relationship of Nifty 50 and NATCO Pharma Limited"},"content":{"rendered":"<p>Title: Relationship of Nifty 50 and NATCO PharmaLimited<br \/>\nAuthor: Nandni Handa<br \/>\nIntroduction of Company:<br \/>\nNatco Pharma is an Indian multinational pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is a major producer of branded oncology medicines and hepatitis C drugs.<br \/>\nNatco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.<br \/>\nNatco family currently consists of around 5000 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. Natco is well recognized for its innovation in Pharmaceutical R&amp;D.<br \/>\nObjective: To calculate the beta of NATCO Pharma and find its significance.<br \/>\nView and Reviews:<br \/>\n\u2022\tNatco Pharma gains 9% as firm launches generic version of Revlimid in US<br \/>\n\u2022\tNatco Pharma gains 9% as firm launches generic version of Revlimid in US<br \/>\n\u2022\tNATCO Pharma&#8217;s (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year<br \/>\nData Collection:<br \/>\n\u2022\tThe data of the company and Nifty 50 (index) has been downloaded from nseindia.com.<br \/>\n\u2022\tThe Friday returns were then calculated as per the weekday.<br \/>\n\u2022\tThe data of the company was then regressed with Nifty 50 by using data analysis technique.<br \/>\n\u2022\tThe company data is independent variable (Y) whereas the Nifty 50 data is dependent variable (X).<br \/>\nData Analysis:<br \/>\nY^= 0.223953 \u2013 0.11233X<br \/>\nWhere Y = NATCO Pharma<br \/>\nIn the data, n= 47; R^2= 0.002879; F-stat= 0.129937<br \/>\nThe above regression equation tells us the relationship between X and Y, where Y= NATCO Pharma and X= Nifty 50 prices.<br \/>\nThe negative sign tells us there is indirect relationship between them, if the price rises of Nifty 50 then the price of NATCO Pharma decreases  and vice versa.<br \/>\nR^2 is 0.002879 which means 2.879% of Y is explained by X and the balance is error.<br \/>\nF= 0.129937 which is more than the table value, which means overall the model is statistically significant at 5% level.<br \/>\nConclusion:<br \/>\nBased on the research methodology and data analysis performed we can conclude that only 2.879% of NATCO Pharma can be explained by Nifty 50 and the remaining is attributed to the fundamentals and the policies of NATCO Pharma.<br \/>\nSince F value is greater than the table value, b value is significant. The model can be relied upon to analyse the risk factors and the analysis can depend on this model<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Title: Relationship of Nifty 50 and NATCO PharmaLimited Author: Nandni Handa Introduction of Company: Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is a major producer of branded oncology medicines and hepatitis C drugs. Natco Pharma Limited was incorporated in Hyderabad in&hellip; <a class=\"more-link\" href=\"http:\/\/www.sachdevajk.in\/?p=16038\">Continue reading <span class=\"screen-reader-text\">Relationship of Nifty 50 and NATCO Pharma Limited<\/span><\/a><\/p>\n","protected":false},"author":91976,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38,9],"tags":[],"class_list":["post-16038","post","type-post","status-publish","format-standard","hentry","category-finance","category-management","entry"],"_links":{"self":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts\/16038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/users\/91976"}],"replies":[{"embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16038"}],"version-history":[{"count":1,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts\/16038\/revisions"}],"predecessor-version":[{"id":16156,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts\/16038\/revisions\/16156"}],"wp:attachment":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16038"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}